Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Curis ( (CRIS) ).
On November 6, 2025, Curis completed the sale of its Erivedge Business to TPC Investments Royalty LLC, managed by Oberland, for $2.5 million and a release of liability related to future royalties. This transaction will result in a gain for Curis in the fourth quarter of 2025 and extinguish its royalty-related liabilities, although it will no longer receive revenues under the License Agreement. Additionally, Curis is actively pursuing compliance with Nasdaq listing requirements after receiving an exception period until November 14, 2025, to meet the market value listing standard. The company is also advancing its clinical studies in PCNSL, CLL, and AML, with significant progress in enrolling patients and presenting data at upcoming conferences, which could potentially enhance its market positioning and stakeholder confidence.
The most recent analyst rating on (CRIS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.
Spark’s Take on CRIS Stock
According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.
Curis’ overall stock score is primarily impacted by its weak financial performance and valuation. The company’s ongoing financial challenges and negative equity are significant concerns. Technical indicators suggest a bearish trend, while the earnings call provides some positive developments in clinical trials but is overshadowed by cash runway concerns.
To see Spark’s full report on CRIS stock, click here.
More about Curis
Curis, Inc. is a biotechnology company focused on developing emavusertib, an orally available small molecule IRAK4 inhibitor. The company is engaged in clinical studies for conditions such as primary central nervous system lymphoma (PCNSL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL), with emavusertib being evaluated in various combinations and as a monotherapy.
Average Trading Volume: 70,424
Technical Sentiment Signal: Sell
Current Market Cap: $18.25M
Learn more about CRIS stock on TipRanks’ Stock Analysis page.